Cardiome Pharma Corp. (CRME) Misses Q3 Loss Views by 2c
Get Alerts CRME Hot Sheet
Join SI Premium – FREE
Cardiome Pharma Corp. (NASDAQ: CRME) reported Q3 loss of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $960 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Canadian National Railway (CNI) Tops Q3 EPS by 8c
- Capri Holdings Limited (CPRI) Tops Q2 EPS by 21c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share